Actively Recruiting
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Led by Second Affiliated Hospital of Guangzhou Medical University · Updated on 2024-06-26
50
Participants Needed
1
Research Sites
800 weeks
Total Duration
On this page
Sponsors
S
Second Affiliated Hospital of Guangzhou Medical University
Lead Sponsor
G
Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.
CONDITIONS
Official Title
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Solid advanced malignant tumors
- Age between18 and 80 years
- Life expectancy is greater than three months
You will not qualify if you...
- Benign tumor
- Life expectancy is less than three months
- Serious medical comorbidity
- Others
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510260
Actively Recruiting
Research Team
Z
Zhenfeng Zhang, MD, PhD
CONTACT
B
Bingjia He, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here